

Ticker: GXU CN Cash: C\$10m Project: Madaouela/Mutanga

Market cap: C\$225mPrice: C\$0.39/shCountry: NigerRECOMMEND. (unc.): BUYTARGET (unc.): C\$0.70/shRISK RATING: HIGH

Recall our thesis on GoviEx: In a time of rising uranium prices and a lack of actionable new supply, GoviEx has actionable projects that can be developed quickly, significant resource tail and operating margin torque to higher prices, and well-connected management that can advance discussions with utilities, governments and potential M&A. With the flagship Madaouela project (Niger) well advanced towards feasibility study and permits in place, we think GoviEx can surface value at Mutanga (Zambia, 60Mlbs at 283ppm U308), and this year's infill, resource upgrade and DFS study program should do just that, advancing the project to a stage where the market can value it more fully and potential partners can evaluate taking a project stake. We maintain our BUY rating and C\$0.70/sh PT based on. Stepping back, we think uranium is still a trade with significant upside with macro positive catalysts including contracting supporting the U\$60/lb base case but new reactor builds and energy security in mature US/EU/developed APAC serving as a source of additional demand. We think permitted Australian and US assets, while logically the first movers, are now well valued, and see greater value in lower head grade African projects, or world-class Athabasca development assets. Of these we like GoviEx's combination of actionable projects, connected management and attractive valuation.

Figure 1. Mutanga resource estimate by deposit

		Measured			Indicated			Inferred			Resources (Total Contained)			Strip	In-situ @US\$60/Ib	
		Tonnes	U308 grade	U308	Tonnes	U308 grade	U308	Tonnes	U308 grade	U308	Tonnes	U308 grade	U308	Ratio		
Property	Туре	(Mt)	(ppm)	(Mibs)	(Mt)	(ppm)	(Mibs)	(Mt)	(ppm)	(Mlbs)	(Mt)	(ppm)	(Mibs)	(x)	(\$/t)	\$m
Mutanga	UG	1.9	481	2.0	8.4	314	5.8	7.2	206	3.3	17.5	288	11.1	1.4	38.1	666
Dibwe	OP							17.0	239	9.0	17.0	239	9.0	2.9	31.6	537
Dibwe East	UG							43.1	304	28.9	43.1	304	28.9	4.2	40.2	1,733
Gwabe	UG	1.3	237	0.7	3.6	313	2.5	0.7	178	0.3	5.6	278	3.4	1.9	36.8	206
Njame	UG	2.7	350	2.1	3.7	252	2.1	2.1	225	1.0	8.5	276	5.2	6.0	36.6	311
Njambe South	UG							4.4	250	2.4	4.4	250	2.4		33.1	146
Total		5.9	367	4.8	15.7	299	10.4	74.5	273	44.9	96.1	283	60.0	3.4	37.5	3,599

Source: Goviex, as at 20 November 2017, Resources not pit constrained by within 125m of surface, c/o 100ppm, strip ratio based on PEA mine inventory rather than total MRE tonnes

Mutanga update: Infill drilling to support reserves on low capex 2.6Mlbs pa heap leach

GoviEx reported commencement of 2022 fieldwork at its Mutanga uranium heap leach project in Zambia. 15,500m of infill percussion drilling to $120m \times 50m$ spacing to a depth of 120m is planned, primarily at the Dibwe East (MRE: 28.9Mlbs at 304ppm U_3O_8 , PEA inventory) to upgrade inferred to indicated for the planned DFS. Other planned work includes 9,000m of DD for core samples, a hydrogeological study to confirm water supply, and an update of the ESIA and relocation action plan. The 2017 PEA scoped an 11-year 2.6Mlb U_3O_8 production per year heap leach operation with US\$123m initial capex and US\$31.1/lb operating costs with LOM 3.4 strip ratio.

Why we like Goviex

- Large, permitted, well drilled flatship with 20-year 2.5Mlb DFS @ US\$60/lb at Madaouela
- Low strip, on infrastructure 2.6 Mlb pa heap leach second project at Mutanga (Zambia)
- Experienced and well connected management to advance portfolio

Catalysts

- 2022: Madaouela DFS, offtake and finance
- 2023: SCPe Madaouela construction start (price dependent)
- 1H25: SCPe first production at Madaouela
- 1H27: SCPe first production at Mutanga

Research

Brock Salier (London) M: +44 7400 666 913 <u>bsalier@sprott.com</u> **Justin Chan** (London) M: +44 7554 784 688 <u>jchan@sprott.com</u>



Brandon Gaspar (Toronto) M: +1 437 533 3142 <u>bgaspar@sprott.com</u> **Eleanor Magdzinski** (Toronto) M: +1 705 669 7456 <u>emagdzinski@sprott.com</u>

Ticker: GXU CN	Price / mkt	сар:	C\$0.39/sh,			Market P/NAV:	0.51x C\$0.77/sh		Assets:	Madauoela	
J Chan / B Gaspar / E Magdzinski	Rec / PT:		BUY / C\$0.	70		1xNAV _{2Q20} FD:	C∌U.777SN		Country:	Niger	
Group-level SOTP valuation	4Q21	1Q22				Share data					
		US\$m	0/ship	NAVx	C\$/sh	Basic shares (m): 576.1	FD + 0	ptions (m):	737.6	FD + FF	1053.2
Madaoela NPV 1Q22		129	80%	1.0x	0.22	Commodity price	CY23E	CY24E	CY25E	CY26E	CY27E
Mutanga NPV 1Q22		118	100%	1.0x	0.20	Uranium price (US\$/lb)	60.0	60.0	60.0	60.0	60.0
Falea (US\$1.5/lb)		66	80% 1.0x		0.11	Ratio analysis	CY23E	CY24E	CY25E	CY26E	CY27E
Central SG&A & fin costs 1Q22		(88)		1.0x	(0.15)	FD shares out (m)	959.6	983.5	1015.1	1048.0	1053.2
Lbs outside mine plan (\$1.50/lb)		171	100%	1.0x	0.29	EPS (US\$/sh)	(0.010)	(0.021)	0.088	0.032	0.053
Exploration		25	100%	1.0x	0.04	CFPS before w/c (US\$/sh)	(0.01)	(0.01)	0.11	0.09	0.11
Cash and restr. cash 4Q21		10		1.0x	0.02	FCFPS pre growth (US\$/sh)	(0.01)	(0.02)	0.02	0.00	0.09
Debt 4Q21 excl convert		(6)		1.0x	(0.01)	FCF/sh (US\$/sh)	(0.18)	(0.21)	0.02	0.00	0.09
ITM options		32		1.0x	0.05	FCF yield - pre growth (%)	(3%)	(5%)	5%	0%	22%
1xNAV8% US\$60/Ib		455			0.77	FCF yield (%)	(45%)	(53%)	5%	0%	22%
Assumed build equity issuance		100			0.09	EBITDA margin (%)			54%	52%	50%
1xNAV fully funded8% US\$60/lb		555			0.66	FCF margin (%)	 (20)		10%	0%	36%
P/NAV (x):		No. deinde			0.59x C\$/sh	ROA (%)	(3%)	(4%)	16%	6%	10%
Target multiples		Multiple 1.00x			0.70	ROE (%)	(6%)	(13%)	35%	12% 11%	16% 18%
Target P/NAV Multiple		1.00x				ROCE (%)	(1%)	(2%)	20%		
Target price Sources			Uses		0.70	EV (US\$m) PER (x)	226 (38.0)	434 (18.5)	428 4.4x	435 12.1v	345 7.3x
Madaoela PFS capex	1124330~	כרווי ז		TM options	IIS¢106m	P/CF (x)	(38.0) nmf	(18.5) nmf	4.4x 2.7x	12.1x 3.3x	7.3x 2.6x
SCPe contingency			•	60% gearing		EV/EBITDA (x)	nmf	nmf	4.0x	5.5x 4.8x	2.7x
SCPe G&A + fin. cost to first Au		IV	_	Build Equity		Income statement	CY23E	CY24E	4.0x	CY26E	CY27E
SCPe G&A + fin. cost to first Au SCPe working capital					US\$100m	Revenue (US\$m)		L124E	200	176	252
	US\$506m		Tot	al proceeds		COGS (US\$m)			(87)	(79)	(121)
1xNAV sensitivity to gold price and		AV multiple		.a. proceeds	וווטטנענט	Gross profit (US\$m)			113	96	131
1xNAV Mines (C\$m)	\$40/lb	\$50/lb	\$60/lb	\$70/lb	\$80/lb	G&A & central	(2)	(5)	(5)	(5)	(5)
10% discount	-211	-7	156	317	477	Depreciation				(39)	(46)
9% discount	-214	10	188	364	539	Impairment & other (US\$m)					
8% discount	-216	30	224	417	610	Net finance costs (US\$m)	(5)	(13)	(19)	(19)	(14)
7% discount	-219	54	266	478	690	Tax (US\$m)					(10)
6% discount	-221	81	313	547	780	Minority interest (US\$m)					
5% discount	-223	112	368	626	884	Net income attr. (US\$m)	(7)	(18)	89	34	56
Valuation (C\$/sh)	\$40/lb	\$50/lb	\$60/lb	\$70/lb	\$80/lb	EBITDA	(5)	(8)	108	91	126
0.50xNAV	neg	0.10	0.35	0.55	0.75	Cash flow	CY23E	CY24E	CY25E	CY26E	CY27E
0.75xNAV	neg	0.15	0.50	0.85	1.15	Profit/(loss) after tax (US\$m)	(10)	(21)	89	34	56
1.00xNAV	neg	0.20	0.70	1.10	1.55	Add non-cash items (US\$m)	5	15	20	59	61
1.25xNAV	neg	0.25	0.85	1.40	1.90	Less wkg cap / other (US\$m)			(19)	2	(8)
1.50xNAV	neg	0.30	1.00	1.65	2.30	Cash flow ops (US\$m)	(5)	(6)	90	94	109
Valuation over time	1Q22E	1Q23E	1Q24E	1Q25E	1Q25E	PP&E (US\$m)	(159)	(181)	(50)	(74)	(2)
Mines NPV (US\$m)	240	261	454	686	672	Other (US\$m)					
Cntrl G&A & fin costs (US\$m)	(88)	(89)	(85)	(70)	(29)	Cash flow inv. (US\$m)	(159)	(181)	(50)	(74)	(2)
Net cash at 1Q (US\$m)	10	55	(146)	(131)	(128)	Debt draw (repayment) (US\$m)	100	100			(100)
Other Assets + Options	293	293	293	293	293	Equity issuance (US\$m)	114	1	10	3	
1xNAV (US\$m)	455	520	516	778	809	Other (US\$m)	95	(15)	(35)	(20)	(15)
P/NAV (x):	0.5x	0.6x	0.6x	0.4x	0.4x	Cash flow fin. (US\$m)	309	86	(25)	(17)	(115)
1xNAV share px FD (C\$/sh)	0.74	0.68	0.66	0.96	0.96	Net change post forex (US\$m)	145	(101)	15	3	(8)
ROI to equity holder (% pa)	89%	32%	19%	25%	20%	FCF (US\$m)	(169)	(202)	20	0	92
Resource / Reserve	Mt	ppm U308	Mlbs	EV/lb		Balance sheet	CY23E	CY24E	CY25E	CY26E	CY27E
Measured, ind. & inf Madoeula	46	1,351	138.4	1.31		Cash (US\$m)	155	54	69	72	64
Measured, ind. & inf Total Attr	149	614	201.6	0.90		Accounts receivable (US\$m)			8	7	10
Group 2P Reserves	25	845	46.4	3.90		Inventories (US\$m)			22	20	30
Production (100%)	CY25E	CY26E	CY27E	CY28E	CY29E	PPE & exploration (US\$m)	231	412	462	498	453
Madaouela (000mlbs U308)	3.3	2.9	2.7	2.3	2.2	Other (US\$m)	0	0	0	0	0
Mutanga (000mlbs U308)			1.5	2.6	2.4	Total assets (US\$m)	386	466	561	596	557
Group cash cost (US\$/lb)	21.72	25.33	30.65	31.62	29.46	Debt (US\$m)	100	200	200	200	100
Group AISC (US\$/lb)	28.83	30.49	34.19	37.67	43.39	Other liabilities (US\$m)	108	141	136	121	111
Madaouela (000ml	bs U308)		Mutanga (00	0mlbs U308	3)	Shareholders equity (US\$m)	407	408	418	421	421
8mlbs			<u> </u>		US\$40/oz US\$30/oz	Retained earnings (US\$m)	(241)	(262)	(173)	(139)	(83)
6mlbs					US\$30/oz US\$20/oz	Minority int. & other (US\$m)	12	12	12	12	12
2mlbs					US\$10/oz	Liabilities+equity (US\$m)	386	499	594	615	561
						Net Cash	55	(146)	(131)	(128)	(36)
CY25E CY26E	CY27	E CY	′28E	CY29E		Net Debt to NTM EBITDA (x)	nmf	1.3x	1.4x	1.0x	0.3x
•							•				



Equity Research

DISCLOSURES & DISCLAIMERS

This research report (as defined under IIROC Rule 3600, Part B) is issued and approved for distribution in Canada by Sprott Capital Partners LP ("SCP"), an investment dealer who is a member of the Investment Industry Regulatory Organization of Canada ("IROC") and the Canadian Investor Protection Fund ("CIPF"). The general partner of SCP is Sprott Capital Partners GP Inc. and SCP is a wholly-owned subsidiary of Sprott Inc., which is a publicly listed company on the Toronto Stock Exchange under the symbol "SII". Sprott Asset Management LP ("SAM"), a registered investment manager to the Sprott Funds and is an affiliate of SCP. This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP and/or affiliated companies or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivatives instruments thereon, and may, as a principal or agent, buy or sell such products.

DISSEMINATION OF RESEARCH:

SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a predetermined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact unsubscribe@sprott.com and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

RESEARCH ANALYST CERTIFICATION:

Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party
 except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

UK RESIDENTS:

Sprott Partners UK Limited ("Sprott") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to buy or sell any security. Sprott and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by Sprott's clients as part of their advisory services to them or is short term market commentary. Neither Sprott nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Sprott Capital Partners LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Sprott Global Resource Investments Ltd. ("SGRIL"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SGRIL accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or



qualified as a research analyst with FINRA and may not be an associated person of SGRIL and, therefore, may not be subject to applicable restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SGRIL representative.

Analyst Certification/Regulation AC

The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Sprott Capital Partners Explanation of Recommendations: Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

BUY: The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

NEUTRAL: The stock's total returns are expected to be in line with the overall market

SELL: The stocks total returns are expected to be materially lower than the overall market

TENDER: The analyst recommends tendering shares to a formal tender offering

UNDER REVIEW: The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a re-evaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

NOT RATED ((N/R): The stock is not currently rated **NOT RATED ((N/R):** The stock is not currently rated

Research Disclosure						
1	SCP and its affiliates collectively beneficially owns 1% or more of any class of the issuer's equity securities ¹					
2	The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives	YES				
3	An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services	NO				
4	SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation	NO				
5	Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer	NO				
6	SCP is making a market in an equity or equity related security of the issuer	NO				
7	The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer	NO				
8	The analyst has conducted a site visit and has viewed a major facility or operation of the issuer	NO				
9	The analyst has been reimbursed for travel expenses for a site visit by the issuer	NO				

Sprott Capital Partners Equity Research Ratings:

Summary of Recommendations as of April 2022					
BUY:	55				
HOLD:	1				
SELL:	0				
UNDER REVIEW:					
TENDER:	0				
NOT RATED:	0				
TOTAL	56				

¹ As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month

